‘Murderbot' Renewed For Season 2 At Apple TV+ Ahead Of Season 1 Finale
The renewal news on Thursday comes ahead of the conclusion of the first season, which debuts on Friday.
More from Deadline
2025 TV Series Renewals: Photo Gallery
'Virgin River' Gets Early Season 8 Renewal, Becomes Netflix's Longest-Running Scripted Series
'Slow Horses' Renewed For Season 7 At Apple TV+
Based on the first novella in Martha Wells' book series, Murderbot is a sci-fi thriller/comedy about a self-hacking security construct who is horrified by human emotion yet drawn to its vulnerable clients, played by Alexander Skarsgård.
In Season 1, Murderbot must hide its free will and complete a dangerous assignment when all it really wants is to be left alone to watch futuristic soap operas and figure out its place in the universe.
In addition to starring in the series, Skarsgård also serves as an executive producer. Murderbot is created by Chris and Paul Weitz, who are also the showrunners.
'We're so grateful for the response that Murderbot has received, and delighted that we're getting to go back to Martha Wells' world to work with Alexander, Apple, CBS Studios and the rest of the team,' Chris and Paul Weitz, said in a statement Thursday.
Added Matt Cherniss, head of programming, Apple TV+: 'Chris, Paul, Alexander and the entire Murderbot team have delivered a brilliantly original, addictive, witty and vibrant adaptation that has captured the imagination of audiences everywhere. We can't wait to unveil what's next for Murderbot and, of course, 'Sanctuary Moon' in season two.'
In addition to Skarsgård, the Season 1 ensemble cast includes Noma Dumezweni, David Dastmalchian, Sabrina Wu, Akshay Khanna, Tattiawna Jones and Tamara Podemski.
Murderbot hails from CBS Studios. The Weitz brothers write, direct and executive produce under their Depth of Field banner. Andrew Miano also executive produces for Depth of Field. David S. Goyer executive produces alongside Keith Levine for Phantom Four. Wells serves as consulting producer.
Best of Deadline
'The Buccaneers' Season 2 Release Schedule: When Do New Episodes Come Out?
'The Buccaneers' Season 2 Soundtrack: From Griff To Sabrina Carpenter
2025 TV Series Renewals: Photo Gallery
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
27 minutes ago
- TechCrunch
TikTok is adding features for songwriters to its app
TikTok is adding new features to its app to let songwriters highlight their works. These features, rolling out in beta, include a 'Songwriter' label and a new tab on their profile to show off their musical works. This can help songwriters market themselves better to potential clients. The company said a limited number of publishing partners and songwriters have access to the new label and the music highlight section. Songwriters and publishers who want to be part of the program will have to join a waitlist for now. TikTok said that it surveyed over 870 songwriters and interviewed a bunch of them to understand their needs on social media in relation to profile building and the creation of monetization opportunities. The company also pointed to an independent survey, which indicated that more than half of songwriters use social media to raise their profile use TikTok to do it. The Bytedance-owned apps said that outcome of these surveys drove the decision to build these features. Image Credits: TikTok 'We are passionately committed to supporting songwriters at TikTok, which is why we built these tools to celebrate and elevate songwriters and their work on our platform,' TikTok's Global Head of Music Publishing Licensing and Partnership said in a sentence. 'TikTok is unique in its ability to offer songwriters a way to highlight their musical works alongside their own content, helping them to tell stories about their music, their craft, and their lives, and to raise their profile and build their audience on TikTok, as hundreds of thousands of artist creators already do.' Notably, Spotify has been releasing features to let songwriters highlight their work for years now. Last year, Tidal went beyond just highlighting songwriter works and launched a tool to track their royalties and manage their work for which they have songwriting credits. While TikTok decided to shut down its music streaming service TikTok Music last year, the platform still remains important for users to discover new music and for artists to promote their tracks. Earlier this year, the company released a TikTok for Artists tool to let artists monitor the performance of their campaign and tracks.
Medscape
27 minutes ago
- Medscape
Long-Term Rimegepant Use Safe for Migraine Prevention
TOPLINE: The use of the calcitonin gene-related peptide (CGRP) antagonist rimegepant 75 mg for 52 weeks showed a favorable safety profile and sustained benefits for migraine prevention in a new open-label extension (OLE) study. The treatment was associated with a reduction in monthly migraine days (MMDs), as well as a low frequency of adverse events (AEs) and no significant hepatic safety concerns. METHODOLOGY: The original phase 2/3 multicenter, randomized, double-blind, placebo-controlled trial included adult participants who had 4-18 moderate-to-severe migraine attacks per month. As reported previously, participants who received one tablet of rimegepant 75 mg every other calendar day for 12 weeks had significantly fewer MMDs than those who received matching placebo, meeting the primary endpoint. The treatment phase was then followed by a 52-week OLE period, where safety and tolerability were assessed through AE monitoring, vital signs assessments, physical examinations, ECGs, and laboratory tests, with special attention to hepatic-related AEs. All OLE participants received the active anti-CGRP. Exploratory outcomes during the extension period included the mean reduction in the number of MMDs and the proportion of participants achieving ≥ 50% and 100% reductions in the number of MMDs. TAKEAWAY: Among 603 participants who entered the OLE period, 71% of the participants completed the study; 52% experienced at least one AE, with most deemed to be mild. Only 2% of participants reported serious AEs, none of which were related to the liver or related to the study drug. Treatment-related AEs occurred in 15% of participants, leading to drug discontinuation in 3%. The most common AEs reported were constipation, upper respiratory tract infection, nausea, migraine, increased liver enzymes, and weight gain, although each occurred in ≤ 1% of participants. The hepatic safety profile was favorable, and liver-related AEs were rare. The mean number of MMDs decreased by 6.2 d/mo over the OLE period, with sustained and increasing treatment benefits being observed without a decrease in the effect. The proportion of participants achieving ≥ 50% and 100% reductions in the number of MMDs increased during the extension period. IN PRACTICE: 'This trial found that participants who took rimegepant every other day and as needed (up to one 75 mg tablet a day) experienced a reduction in migraine days and experienced few side effects. Moreover, the treatment benefits of rimegepant increased over a 1-year period without losing effectiveness,' the investigators wrote. SOURCE: This study was led by David Kudrow, MD, California Medical Clinic for Headache, Santa Monica, California. It was published online on June 30 in Headache. LIMITATIONS: Key limitations included the exclusion of participants with extremely frequent headaches (> 18 headache days per month), which limited the generalizability of the findings. The requirement for a consistent ≥ 50% monthly reduction may have underestimated sustained efficacy, post-randomization dropouts may have skewed the OLE sample, the lack of an active comparator may have introduced bias, and participants' awareness of receiving the drug may have affected reporting. Efficacy endpoints were also exploratory, so definitive conclusions on long-term effectiveness could not be drawn. DISCLOSURES: This study was funded by Biohaven Pharmaceuticals. Several investigators reported having financial or employment ties with the funder or other pharmaceutical companies. One investigator also reported being on the editorial board of journals, including Headache. Full details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Fox News
28 minutes ago
- Fox News
The Quiz #469 – On Your Last Legs
Think you've got the stamina to finish this quiz, or are you about to hit the wall? Play. Share. Listen with Miss America 2025, Abbie Stockard.
